Phase IIB/III Of TG4010 Immunotherapy In Patients With Stage IV Non-Small Cell Lung Cancer
Status:
Terminated
Trial end date:
2016-07-01
Target enrollment:
Participant gender:
Summary
This is a Phase IIb/III randomized, double-blind, placebo-controlled study to compare the
efficacy and safety of first-line therapy combined with TG4010 or placebo in stage IV
non-small cell lung cancer (NSCLC).
TG4010 is a suspension of recombinant Modified Vaccinia virus strain Ankara (MVA strain)
carrying coding sequences for human MUC1 antigen and human interleukin-2 (IL2). TG4010 has
been developed for use as an immunotherapy in cancer patients whose tumors express the MUC1
antigen.
TG4010 is intended to induce a MUC1-specific cellular immune response and to produce a
non-specific activation of several components of the immune system.